Leukemia refers to the group of blood cancer that usually develops in the bone marrow, resulting in the formation of abnormal blood cells. Leukemia is subdivided into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias that include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The increased prevalence rate of CML and the obtainability of huge number of treatment options make this type of blood cancer to hold the largest share in the global leukemia therapeutics market.
In US, more than 60,000 people were estimated to be diagnosed with leukemia in 2019. Approximately 10,670 people died of AML in 2018. In Europe, nearly 30,000 people had CLL in 2018. The upsurge in leukemia cases across the globe has elevated global leukemia therapeutics market.
The presence of established healthcare infrastructure, a high patient base for the disease, increasing awareness on personalized medicine, and the existence of reputed players in the region make North America a dominant shareholder in the global leukemia therapeutics market. There are many new drug launches, approval, development, and funding related to leukemia drugs owing to the increased patient base across the globe. Growing investment in R&D for the development of the new drugs, promising pipeline, and opportunities in emerging economies are anticipated to enhance the revenue of the leukemia therapeutics market in the next five years. The market is growing at a steady rate with a CAGR of 6.2% during the forecast period 2019–2025.